235 related articles for article (PubMed ID: 33909614)
21. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
22. Molecular findings in myeloid neoplasms.
Tran TB; Siddon AJ
Int J Lab Hematol; 2023 Aug; 45(4):442-448. PubMed ID: 37345257
[TBL] [Abstract][Full Text] [Related]
23. Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay.
Ferrone CK; Wong H; Semenuk L; Werunga B; Snetsinger B; Zhang X; Zhang G; Lui J; Richard-Carpentier G; Crocker S; Good D; Hay AE; Quest G; Carson N; Feilotter HE; Rauh MJ
J Mol Diagn; 2021 Oct; 23(10):1292-1305. PubMed ID: 34365012
[TBL] [Abstract][Full Text] [Related]
24. Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome.
Kim YJ; Jung SH; Hur EH; Choi EJ; Lee KH; Park HC; Kim HJ; Kwon YR; Park S; Lee SH; Chung YJ; Lee JH
Leuk Res; 2021 Apr; 103():106540. PubMed ID: 33667811
[TBL] [Abstract][Full Text] [Related]
25. Accurate Detection and Quantification of FLT3 Internal Tandem Duplications in Clinical Hybrid Capture Next-Generation Sequencing Data.
Tung JK; Suarez CJ; Chiang T; Zehnder JL; Stehr H
J Mol Diagn; 2021 Oct; 23(10):1404-1413. PubMed ID: 34363960
[TBL] [Abstract][Full Text] [Related]
26. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
27. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
Kohlmann A; Bacher U; Schnittger S; Haferlach T
Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
[TBL] [Abstract][Full Text] [Related]
28. Next-Generation DNA Sequencing-Based Gene Panel for Diagnosis and Genetic Risk Stratification in Onco-Hematology.
Gargallo P; Molero M; Bilbao C; Stuckey R; Carrillo-Cruz E; Hermosín L; Pérez-López O; Jiménez-Velasco A; Soria E; Lázaro M; Carbonell P; Yáñez Y; Gómez I; Izquierdo-García M; Valero-García J; Ruiz C; Such E; Calabria I
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454892
[TBL] [Abstract][Full Text] [Related]
29. A DNA pool of FLT3-ITD positive DNA samples can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation - Testing several different ITD sequences and rates, simultaneously.
Mezei ZA; Tornai D; Földesi R; Madar L; Sümegi A; Papp M; Antal-Szalmás P
J Biotechnol; 2019 Sep; 303():25-29. PubMed ID: 31302157
[TBL] [Abstract][Full Text] [Related]
30. An NGS based MRD evaluation from acute myeloid leukemia patients.
Chen B; Wang L; Wang Z; Zhang H; Chen L; Zhang L; Li J; Yan X; Zhao M; Lin Y; Ru K
Int J Lab Hematol; 2023 Jun; 45(3):353-359. PubMed ID: 36751002
[TBL] [Abstract][Full Text] [Related]
31. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract][Full Text] [Related]
32. Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics.
Alonso CM; Llop M; Sargas C; Pedrola L; Panadero J; Hervás D; Cervera J; Such E; Ibáñez M; Ayala R; Martínez-López J; Onecha E; de Juan I; Palanca S; Martínez-Cuadrón D; Rodríguez-Veiga R; Boluda B; Montesinos P; Sanz G; Sanz MA; Barragán E
J Mol Diagn; 2019 Mar; 21(2):228-240. PubMed ID: 30576870
[TBL] [Abstract][Full Text] [Related]
33. Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.
Larsson N; Lilljebjörn H; Lassen C; Johansson B; Fioretos T
Eur J Haematol; 2012 Feb; 88(2):136-43. PubMed ID: 21933280
[TBL] [Abstract][Full Text] [Related]
34. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
Ronaghy A; Yang RK; Khoury JD; Kanagal-Shamanna R
Curr Hematol Malig Rep; 2020 Jun; 15(3):194-202. PubMed ID: 32382988
[TBL] [Abstract][Full Text] [Related]
35. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Karantanos T; Gondek LP; Varadhan R; Moliterno AR; DeZern AE; Jones RJ; Jain T
Br J Haematol; 2021 Jun; 193(6):1142-1150. PubMed ID: 34028801
[TBL] [Abstract][Full Text] [Related]
36. Analytical Validation of an Automated Semiconductor-Based Next-Generation Sequencing Assay for Detection of DNA and RNA Alterations in Myeloid Neoplasms.
Zbieranski N; Insuasti-Beltran G
J Mol Diagn; 2024 Jan; 26(1):29-36. PubMed ID: 37879438
[TBL] [Abstract][Full Text] [Related]
37. The molecular basis of myeloid malignancies.
Kitamura T; Inoue D; Okochi-Watanabe N; Kato N; Komeno Y; Lu Y; Enomoto Y; Doki N; Uchida T; Kagiyama Y; Togami K; Kawabata KC; Nagase R; Horikawa S; Hayashi Y; Saika M; Fukuyama T; Izawa K; Oki T; Nakahara F; Kitaura J
Proc Jpn Acad Ser B Phys Biol Sci; 2014; 90(10):389-404. PubMed ID: 25504228
[TBL] [Abstract][Full Text] [Related]
38. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T
Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608
[TBL] [Abstract][Full Text] [Related]
39. [Significance of Targeted Sequencing Assay for Patients with Suspected Myeloid Malignancies].
Zhang LJ; Shi YY; Chen Y; Deng Y; Ding YH; Li Z; Chen KK; Ding BH; Wang CL; Yu L; He ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1985-1990. PubMed ID: 33283730
[TBL] [Abstract][Full Text] [Related]
40. Clinical performance and utility of a comprehensive next-generation sequencing DNA panel for the simultaneous analysis of variants, TMB and MSI for myeloid neoplasms.
Sahajpal NS; Mondal AK; Ananth S; Njau A; Ahluwalia P; Jones K; Ahluwalia M; Okechukwu N; Savage NM; Kota V; Rojiani AM; Kolhe R
PLoS One; 2020; 15(10):e0240976. PubMed ID: 33075099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
